Comerica Bank Sells 154,467 Shares of Insmed, Inc. $INSM

Key Points

• Comerica Bank sharply reduced its stake in Insmed, selling 154,467 shares in the fourth quarter and cutting its holdings by 95.5% to just 7,337 shares worth about $1.28 million.
• Insmed’s latest quarterly results beat expectations on both earnings and revenue, with EPS of -$0.76 versus an expected -$0.90 and revenue of $305.96 million, up 229.7% year over year.
• Despite the earnings beat, the stock remains under pressure as investors weigh insider selling, higher expenses, and concerns that 2026 revenue guidance may fall short of consensus, even though analysts still largely rate the stock a Buy.

Comerica Bank lowered its holdings in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) by 95.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 7,337 shares of the biopharmaceutical company's stock after selling 154,467 shares during the quarter. Comerica Bank's holdings in Insmed were worth $1,277,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. CoreCap Advisors LLC acquired a new stake in Insmed during the fourth quarter worth about $27,000. GraniteShares Advisors LLC purchased a new stake in Insmed in the fourth quarter valued at $30,000. CIBC Private Wealth Group LLC grew its stake in shares of Insmed by 42.1% in the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 53 shares in the last quarter. Stone House Investment Management LLC acquired a new stake in shares of Insmed in the third quarter valued at $29,000. Finally, SBI Securities Co. Ltd. grew its stake in Insmed by 404.9% during the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 166 shares in the last quarter.

Insmed Trading Down 3.6%

INSM opened at $101.17 on Friday. The company has a current ratio of 3.83, a quick ratio of 3.54 and a debt-to-equity ratio of 0.76. Insmed, Inc. has a 12 month low of $64.85 and a 12 month high of $212.75. The firm's fifty day simple moving average is $145.87 and its 200 day simple moving average is $165.46. The stock has a market capitalization of $21.84 billion, a P/E ratio of -17.60 and a beta of 0.89.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.90) by $0.14. The firm had revenue of $305.96 million for the quarter, compared to analyst estimates of $300.81 million. Insmed had a negative net margin of 144.44% and a negative return on equity of 121.03%. The company's revenue was up 229.7% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.42) EPS. As a group, research analysts anticipate that Insmed, Inc. will post -2.41 EPS for the current fiscal year.

Insider Activity at Insmed

In other Insmed news, CEO William Lewis sold 13,396 shares of the company's stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $147.79, for a total value of $1,979,794.84. Following the completion of the transaction, the chief executive officer directly owned 301,185 shares in the company, valued at approximately $44,512,131.15. This represents a 4.26% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Michael Alexander Smith sold 19,638 shares of the company's stock in a transaction that occurred on Monday, March 30th. The shares were sold at an average price of $150.98, for a total transaction of $2,964,945.24. Following the completion of the transaction, the insider owned 51,871 shares of the company's stock, valued at approximately $7,831,483.58. This trade represents a 27.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 174,589 shares of company stock valued at $27,441,807 in the last quarter. Insiders own 2.10% of the company's stock.

Trending Headlines about Insmed

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Insmed reported Q1 EPS of -$0.76, beating estimates, and revenue rose 229.7% year over year to $306 million. The company also reiterated major 2026 commercial goals, including at least $1 billion in BRINSUPRI revenue and $450 million to $470 million in ARIKAYCE revenue. Article: Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Analysts at Royal Bank of Canada and Wells Fargo cut their price targets but kept bullish ratings, signaling they still see meaningful upside from current levels. RBC lowered its target to $205 from $220 and Wells Fargo cut to $160 from $177. Article: Benzinga report on RBC price target cut Article: The Fly report on Wells Fargo price target cut
• Neutral Sentiment: Insmed also highlighted progress on its pipeline and commercialization efforts, including positive ENCORE study results for ARIKAYCE and the start of the PALM-PAH study for TPIP. These updates support the long-term story, but they are less likely to move the stock immediately. Article: Insmed Q1 2026 Financial Results and Business Update
• Negative Sentiment: The stock is under pressure because Q1 sales came in below expectations and the company’s implied 2026 revenue guidance was below consensus, raising concerns that launch momentum may not be matching investor hopes. Article: Insmed's Q1 Earnings Beat, Sales Miss Estimates, Stock Tanks 23%
• Negative Sentiment: Higher first-quarter expenses also weighed on sentiment, with market commentary pointing to increased costs as another reason investors sold the shares after earnings. Article: Insmed Shares Tumble Amid Higher 1Q Expenses

Wall Street Analysts Forecast Growth

Several analysts have commented on INSM shares. Leerink Partners upped their price objective on Insmed from $210.00 to $215.00 and gave the company an "outperform" rating in a research note on Tuesday, March 24th. Truist Financial set a $205.00 price target on Insmed in a report on Monday, January 12th. HC Wainwright restated a "buy" rating on shares of Insmed in a research note on Friday. Raymond James Financial assumed coverage on shares of Insmed in a report on Friday, April 10th. They issued an "outperform" rating and a $200.00 target price on the stock. Finally, Wells Fargo & Company dropped their target price on Insmed from $177.00 to $160.00 and set an "overweight" rating on the stock in a report on Friday. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Insmed has an average rating of "Buy" and an average target price of $211.86.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company's principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.